Pedro Cabrales

Bioengineering University of California, San Diego, La Jolla, CA 
"Pedro Cabrales"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Jani VP, Jelvani A, Moges S, et al. (2017) Polyethylene Glycol Camouflaged Earthworm Hemoglobin. Plos One. 12: e0170041
Fens MH, Cabrales P, Scicinski J, et al. (2016) Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Medical Oncology (Northwood, London, England). 33: 85
Díaz-Trelles R, Scimia MC, Bushway P, et al. (2016) Notch-independent RBPJ controls angiogenesis in the adult heart. Nature Communications. 7: 12088
Cabrales P, Scicinski J, Reid T, et al. (2016) A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity? Medical Oncology (Northwood, London, England). 33: 63
Cordes T, Wallace M, Michelucci A, et al. (2016) Immunoresponsive gene 1 and itaconate inhibit succinate dehydrogenase to modulate intracellular succinate levels. The Journal of Biological Chemistry
Carter CA, Oronsky BT, Caroen SZ, et al. (2016) RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. Case Reports in Oncology. 9: 171-6
Oronsky B, Scicinski J, Ning S, et al. (2016) RRx-001, A novel dinitroazetidine radiosensitizer. Investigational New Drugs
Kar M, Vernon Shih YR, Velez DO, et al. (2016) Poly(ethylene glycol) hydrogels with cell cleavable groups for autonomous cell delivery. Biomaterials. 77: 186-97
Carter CA, Schmitz B, Peterson PG, et al. (2016) Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001 Case Reports in Oncology. 164-170
Carter CA, Oronsky B, Caroen S, et al. (2016) Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC Respiratory Medicine Case Reports. 18: 62-65
See more...